TY - JOUR T1 - Hepatic Resection Followed by Hepatic Arterial Infusion Chemotherapy for Hepatocellular Carcinoma with Intrahepatic Dissemination JF - Anticancer Research JO - Anticancer Res SP - 525 LP - 531 VL - 38 IS - 1 AU - KUNITAKA KURAMOTO AU - TORU BEPPU AU - HIDETOSHI NITTA AU - KATSUNORI IMAI AU - TOSHIRO MASUDA AU - TATSUNORI MIYATA AU - YUKI KOGA AU - YUKI KITANO AU - TAKAYOSHI KAIDA AU - SHIGEKI NAKAGAWA AU - HIROHISA OKABE AU - HIROMITSU HAYASHI AU - DAISUKE HASHIMOTO AU - YO-ICHI YAMASHITA AU - AKIRA CHIKAMOTO AU - KEN KIKUCHI AU - HIDEO BABA Y1 - 2018/01/01 UR - http://ar.iiarjournals.org/content/38/1/525.abstract N2 - Background/Aim: To investigate the utility of adjuvant hepatic arterial infusion chemotherapy (HAIC) following hepatectomy for patients with hepatocellular carcinoma (HCC) with intrahepatic dissemination (IHD) after local ablation therapy. Patients and Methods: Twelve patients with HCC with IHD were divided into two groups: HAIC group (n=6) underwent hepatectomy followed by HAIC; and the non-HAIC group (n=6) underwent hepatectomy alone. HAIC with cisplatin and 5-fluorouracil was started within a month and was continued for a month: Results: At the first local ablation, tumors close to the major portal vein and insufficient ablation were recognized in eight (67.7%) and six (58.3%) of the patients, respectively. In the HAIC group, the 1-, 3-, and 5-year disease-free and overall survival rates were 50.0%, 16.7%, and 16.7%, and 83.3%, 83.3% and 62.5%, respectively. Three patients in the HAIC group remain alive after 10 years of follow-up. Conclusion: Hepatic resection with short-term postoperative HAIC may provide excellent outcomes in patients with HCC and IHD. ER -